Prospective comparison of peritumoral and subareolar injection of blue dye alone, for identification of sentinel lymph nodes in patients with early stage breast cancer

Journal of Surgical Oncology

Volumn 104, Issue 1, 2011, Pages 37-40

  Kaklamanos, Ioannis G ^a   Birbas, Konstantinos ^a   Syrigos, Konstantinos ^a   Bonatsos, Vasilios G ^b   Bonatsos, Gerasimos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Igias Melathron Hospital   (Greece)

Author keywords

Breast cancer; Sentinel; Technique

Indexed keywords

METHYLENE BLUE;

ADULT; ARTICLE; BREAST AREOLA; BREAST CANCER; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; HUMAN; INJECTION SITE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; COLORING AGENTS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY;

EID: 79958178485     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21897     Document Type: Article

References (31)

1. Krag D, Weaver D, Ashikaga T, et al.: The sentinel node in breast cancer. A multicenter validation study. N Engl J Med 1998;339:941-946. (Pubitemid 28455095)
2. Veronesi U, Paganelli G, Viale G, et al.: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546-553. (Pubitemid 36951366)
3. Giuliano AE, Kirgan DM, Guenther JM, et al.: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;3:391-401. (Pubitemid 24313232)
4. Simmons RM, Smith SM, Osborne MP: Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Breast J 2001;7:181-183. (Pubitemid 32619780)
5. Moffat FL, Jr, Gulec SA, Sittler SY, et al.: Unfiltered sulfur colloid and sentinel node biopsy for breast cancer: Technical and kinetic considerations. Ann Surg Oncol 1999;6:746-755. (Pubitemid 30013651)
6. Shen P, Glass EC, DiFronzo LA, et al.: Dermal versus intraparenchymal lymphoscintigrafy of the breast. Ann Surg Oncol 2001;8:241-248. (Pubitemid 32294805)
7. Veronesi U, Paganelli G, Viale G, et al.: Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series. J Natl Cancer Inst 1999;17:368-373. (Pubitemid 29102337)
8. Haigh PI, Hansen NM, Qi K, et al.: Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 2000;7:21-27. (Pubitemid 30078489)
9. Canavese G, Catturich A, Vecchio C, et al.: Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: Results of randomized trial. Ann Oncol 2009;20:1001-1007.
10. Goyal A, Newcombe RG, Chhabra A, et al.: Factors affecting failed localization and false-negative rate of sentinel node biopsyin breast cancer-results of the ALMANAC validation phase. Breast cancer Res Treat 2006;99:203-208. (Pubitemid 44268268)
11. Albo D, Wayne JD, Hunt KK, et al.: Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg 2001;182:393-398. (Pubitemid 33079094)
12. Leong SP, Donegan E, Heffernon W, et al.: Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol 2000;7:361-366. (Pubitemid 30397478)
13. Krag DN, Anderson SJ, Julian TB, et al.: Technical outcomes of sentinel lymph-node resection and conventional axillarylymph- node dissection in patients with clinically node-negative breast cancer results from the NSABPB-32 randomized phase III trial. Lancet Oncol 2007;8:881-888. (Pubitemid 47488052)
14. Hung WK, Chan CM, Ying M, et al.: Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancet. Br J Surg 2005; 92:1494-1497. (Pubitemid 41785287)
15. McMasters KM, Wong SL, Chao C, et al.: Defining the optimal surgeon experience for breast cancer sentinel node biopsy: A model for implementation of new surgical techniques. Ann Surg 2001;234:292-300. (Pubitemid 32847066)
16. Morrow M, Rademaker AW, Bethke KP, et al.: Learning sentinel node biopsy: Results of a prospective randomized trial of two techniques. Surgery 1999;126:202-714.
17. Krikanova M, Biggar M, Moss D, et al.: Accuracy of sentinel node biopsy for breast cancer using blue dye alone. Breast J 2010;16:384-388.
18. Bines S, Kopkash K, Ali A, et al.: The use of radioisotope combined with isosulfan blue is not superior to radioisotope alone for the identification of sentinel lymph nodes in patients with breast cancer. Surgery 2008;114:606-610.
19. Veronesi U, Paganelli G, Galimberti V, et al.: Sentinelnode biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997;349:1864-1867. (Pubitemid 27270119)
20. Povoski SP, Olsen JO, Young DC, et al.: Prospective randomized clinical trial comparing intradermal, intraparenchymal and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006;13:1411-1421.
21. Lin KM, Patel TH, Ray A, et al.: Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg 2004;199:561-566. (Pubitemid 39420207)
22. Wong SL, Edwards MJ, Chao C, et al.: Sentinel lymph node biopsy for breast cancer: Impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg 2001; 192:684-689.
23. Dabbs DJ, Johnson R: The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J 2004; 10:186-189. (Pubitemid 38715732)
24. Zakaria S, Degnim AC, Kleer CG, et al.: Sentinel lymph node biopsy for breast cancer: How many nodes are enough? J Surg Oncol 2007;96:554-559. (Pubitemid 350191479)
25. Lynch MA, Jackson J, Kim JA, et al.: Optimal number of radioactive sentinel lymph nodes to remove for accurate axillary staging of breast cancer. Surgery 2008;144:525-532.
26. McKarter MD, Yeung H, Borgen PI, et al.: The breast cancer patient with multiple sentinel nodes: When to stop? J Am Coll Surg 2001;192:692-697. (Pubitemid 32506496)
27. Bawer TW, Spitz FR, Callans LS, et al.: Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 2002;9:169-176. (Pubitemid 34259704)
28. Kavallaris A, Camara O, Runnebaum IB: Subareolar only blue dye injection sentinel lymph node biopsy could reduce the numbers of standard axillary lymph node dissection in environments without access to nuclear medicine. J Cancer Res Clin Oncol 2008;134:667-672.
29. Schrenk P, Rehberger W, Shamiyeh A, et al.: Sentinel node biopsy for breast cancer: Does the number of sentinel nodes removed have an impact of the accuracy of finding a positive node? J Surg Oncol 2002;80:130-136. (Pubitemid 34747617)
30. Flett MM, Going JJ, Stanton PD, et al.: Sentinel node localization in patients with breast cancer. Br J Surg 1998;85: 991- 993.
31. Port ER, Patil S, Stempel M, et al.: Number of lymph nodes removed in sentinel lymh-node negative brest cancer patients is significantly related to patient age and tumor size. Cancer 2010;116:1987-1991.